Loading…
Combined detection of SDC2/ADHFE1/PPP2R5C methylation in stool DNA for colorectal cancer screening
Background Colorectal cancer (CRC) is a disease of global concern, and its increasing incidence suggests the need for early and accurate diagnosis. The aim of this study was to investigate the value of combined detection of SDC2, ADHFE1 and PPP2R5C gene methylation in stool samples for early CRC scr...
Saved in:
Published in: | Journal of cancer research and clinical oncology 2023-09, Vol.149 (12), p.10241-10253 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
Colorectal cancer (CRC) is a disease of global concern, and its increasing incidence suggests the need for early and accurate diagnosis. The aim of this study was to investigate the value of combined detection of SDC2, ADHFE1 and PPP2R5C gene methylation in stool samples for early CRC screening.
Methods
Stool samples from patients with CRC (
n
= 105), advanced adenoma (AA) (
n
= 54), non-advanced adenoma (NA) (
n
= 57), hyperplastic or other polyps (HOP) (
n
= 47) or no evidence of disease (NED) (
n
= 100) were collected from September 2021 to September 2022. The methylation levels of SDC2, ADHFE1 and PPP2R5C were quantified by quantitative methylation-specific polymerase chain reaction (qMSP), and faecal immunochemical testing (FIT) was performed. The diagnostic value was assessed using reporter operating characteristic (ROC) curve analysis.
Results
The sensitivity of combined detection of SDC2/ADHFE1/PPP2R5C methylation in predicting CRC (0–IV) was 84.8%, the specificity was 98.0%, and the AUC was 0.930 (95% CI 0.889–0.970). Compared to FIT and serum tumour biomarkers, it showed better diagnostic performance for different stages of CRC.
Conclusion
The results of this study verified that the methylation levels of SDC2, ADHFE1 and PPP2R5C in stool DNA were significantly increased in CRC patients. Combined detection of SDC2/ADHFE1/PPP2R5C methylation is a potential non-invasive diagnostic method for CRC and precancerous lesion screening.
Clinical trial registration
Chinese Clinical Trials Registry, ChiCTR2100046662, registered on 26 May 2021, prospective registration. |
---|---|
ISSN: | 0171-5216 1432-1335 |
DOI: | 10.1007/s00432-023-04943-4 |